Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745755 | 0.85 | PTPN1 (0.46) | SIGMAR1ALDH1A1PTPN2PTPN1HDAC4 | |
| SCHEMBL13041696 | 0.85 | PTPN1 (0.46) | SIGMAR1ALDH1A1PTPN2PTPN1HDAC4 | |
| SCHEMBL3732067 | 0.84 | HTR5A (0.38) | PTPN2PTPN1GPR88 | |
| SCHEMBL3743444 | 0.84 | SIGMAR1 (0.45) | SIGMAR1ALDH1A1MEN1KMT2AHDAC4 | |
| SCHEMBL3745494 | 0.84 | PTPN2 (0.45) | PTPN2PTPN1MEN1KMT2AHDAC4 | |
| SCHEMBL3735483 | 0.83 | PTPN1 (0.43) | ALDH1A1PTPN2PTPN1 | |
| SCHEMBL3736646 | 0.81 | LMNA (0.41) | ALDH1A1PTPN2PTPN1MEN1KMT2A | |
| SCHEMBL3737636 | 0.81 | CA1 (0.42) | ALDH1A1PTPN2PTPN1MEN1KMT2A | |
| SCHEMBL3738515 | 0.80 | TRPV1 (0.47) | ALDH1A1MEN1KMT2AHDAC4 | |
| SCHEMBL3738765 | 0.80 | CA2 (0.41) | PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | SIGMAR1 3365/4885ALDH1A1 765/4885PTPN2 5/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | SIGMAR1 3365/4885ALDH1A1 765/4885PTPN2 5/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | SIGMAR1 3365/4885ALDH1A1 765/4885PTPN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.